Here is a look at four stocks and a big ETF searching for novel therapies in the quest for the growing population in the anti-aging market.
The global anti-aging products and therapies market is expected to grow 54 percent, to US$216.52 billion by 2021—which is up from $140.3 billion, in 2015.
Calico, Human Longevity, and Elysium are some of the big names that dominate headlines in the field—but, for investors looking for opportunities to invest in other companies, there’s more options to invest in the longevity business. The world’s population is always growing older, and with the need to look and feel young as long as possible gives life science companies an increased interest in devices and anti-aging technologies, including a push for items focused on health preservation.
Beyond the aesthetics of aging, “age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits,” said The Business of Anti-Aging Science study. “Some therapeutic approaches – direct-to-consumer nutraceuticals and trial-tested scientific diets – do not require FDA approval, which can significantly reduce their time to market.”
Here, the Investing News Network (INN) provides a brief overview of eight publicly traded anti-aging companies, with options both in the small and large cap sector, as well as a closer look at the Global X Longevity Thematic exchange-traded funds (ETF), which is focused on serving the world’s growing senior population. The companies listed below are in order of market cap size, ranging from largest to smallest. All prices are in US dollars and were taken from Google Finance data at market close Thursday (May 31).
1. Zimmer Biomet (NYSE:ZBH)
Market cap: $22.38 billion; current share price: $111.51
Zimmer Biomet’s focus is on musculoskeletal healthcare. The company designs and manufactures personalized joint replacement technologies. Zimmer’s range of products include uses in orthopedic reconstruction, sports medicine, biologics, extremities and trauma, spine, craniomaxillofacial and thoracic products and dental implants.
Near the end of May, Zimmer has released positive news that the company received 510(k) clearance from the FDA for its Zyston Strut Open Titanium Interbody Space System, making the company’s first titanium spinal implant manufactured via a 3D printing process. As the name of the product suggests, the system of the lumbar cages designed to strengthen, graft capacity and visualization of the interbody spacer in spinal fusion cases.
2. Nu Skin Enterprises (NYSE:NUS)
Market cap: $4.50 billion; current share price: $81.89
Nu Skin Enterprises is a global direct-selling company that markets personal care and nutritional products in 53 markets across the world. Additionally, Nu Skin Enterprises develops and distributes anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. One such anti-aging nutritional supplement is ageLOC R2, which is designed to recharge and renew the body.
At the end of April, the company announced its Q1 financial reporting a 24 percent revenue growth to $616.2 million compared with the prior-year quarter. Other highlights include an 11 percent increase in customers, and as an outlook projects a 15 to 18 percent revenue growth for Q2 and a 10 to 12 percent revenue growth for 2018.
3. Acorda Therapeutics (NASDAQ:ACOR)
Market cap: $1.18 billion; current share price: $26.25
Acorda also focused on people’s longevity is developing therapeutics which restore function and improve people’s lives with neurological disorders. The company already has two marketed FDA-approved therapeutics including Amypra and Qutenza. Some drug candidate’s indications in the company’s pipeline include Parkinson’s disease and multiple sclerosis.
In the company’s Q1 financial results announced in May, Acorda reported an overall lower total revenue from $119.38 million to $106.16 million from the same quarter the previous year and much lower operating income loss from $15.27 million to $454,000.
4. BioTime (NYSEMKT:BTX)
Market cap: $280.36 million; current share price: $2.24
BioTime works in the field of regenerative medicine, human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. It develops therapies that are based on stem cell biology and are intended to rebuild cell and tissue function lost due to degenerative diseases and injury. The products include clinical-stage products in their pipeline and almost approved products such as Renevia, a medical device for cell assisted lipotransfer procedures.
The company reported an expansion to its OpRegen Phase 1 clinical trial in dry-AMD by opening two additional US sites in May. OpRegan is being studied in the trial for the dry form of AMD, which consists of a retinal pigment epithelial (RPE) suspension which are delivered subretinally through a intraocular injection. The new trial sites should begin treating patients in Q2.
5. resTORbio (NASDAQ:TORC)
Market cap: $269.24 million; current share price: $9.79
This biopharmaceutical company has a focus to help people live longer, making it a great fit for our anti-aging stocks list. The company’s lead program is targeting the selective inhibition of TORC1, which is an evolutionary conserved pathway contributing to the decline in function of multiple organ systems, including the immune, cardiac and neurological systems.
In early May, the company released its Q1 financial results which gave an update on its current trial. The company has completed dosing for its Phase 2b study for RTB101 for reducing the incidence of respiratory tract infections. The top line data from this trial is expected to be reported in Q3 2018.
6. CohBar (NASDAQ:CWBR)
Market cap: $242.18 million; current share price: $6.05
This company is taking a different approach to age-related disease through the research and development of mitochondria based therapeutics (MBTs), which is an emerging class of drugs. The novel group of peptides encoded within the mitochondrial genome called mitochondrial-derived peptides (MDPs) have shown to regulate metabolism and cell death, the levels which decline with age.
The company more than doubled its R&D expenses from $1.29 million to $2.68 million from the same quarter the previous year which was announced in CohBar’s Q1 financial results. This was due to costs related to its clinical and investigational drug application (IND)-enabling activities and an increase in stock-based compensation for option grants made.
7. Proteostasis Therapeutics (NASDAQ:PTI)
Market cap: $159.45 million; current share price: $4.84
This biopharmaceutical company, Proteostasis, has a focus on research and development on identifying therapies that restore protein function. The company is developing small molecule therapeutics to treat cystic fibrosis, a disease caused by dysfunctional protein processing and has a partnership with Astellas Pharma (TYO:4503) to research and identify therapies targeting the unfolded protein response pathway.
In May, the company announced the formation of an independent steering committee of lead experts to advise the company on the Phase 3 global clinical development program for PTI-428, the company’s candidate for cystic fibrosis transmembrane conductance regulatory amplifier. This new committee will advise on the design and implementation of the trial.
8. Prana Biotechnology (NASDAQ:PRAN)
Market cap: $18.43 million; current share price: $2.07
Based in Australia, Prana Biotechnology is a development-stage medical biotech company that’s engaged in research related to Alzheimer’s disease, Huntington disease, Parkinson’s disease and other age-related degenerative disorders.
The company’s lead drug candidate, PBT2, is intended to treat Alzheimer’s and Huntington’s diseases, other products are still on the pre-clinical stage. A New Drug Application for Huntington’s disease in 2016/2017 is planned pending positive trial results.
For our investors interested in anti-aging or longevity stocks it’s a good idea to follow this ETF which leads the way with some of the top companies. If you’re unsure if ETFs are for you, take a look at our information page about biotech ETFs to learn more.
Global X Longevity Thematic ETF (NASDAQ:LNGR)
Market cap: $13.07 million; current share price: $20.37
Although it is not a single company focused on the business of longevity or anti-aging, investors should take note of the Global X Longevity Thematic ETF. Started in May 2016, the LNGR ETF provides investors with access to companies focused on increasing lifespans or extending quality of life in advanced age, such as healthcare, pharmaceuticals, and senior living facilities.
LNGR has 99 holdings, 33.72 percent of which are companies in the biotechnology space, and 36.11 percent in healthcare equipment. The large majority of this ETF’s holdings are in the large-cap space.
This is an updated version of an article originally published on the Investing News Network in 2017.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.